A team led by Washington State University researchers have found the bacteria are attracted to the liquid part of blood, or serum, which contains nutrients the bacteria can use as food. One of the chemicals the bacteria seemed particularly drawn to was serine, an amino acid found in human blood that is also a common ingredient in protein drinks.

The research finding, published in the journal eLife, provides new insights into how bloodstream infections occur and could potentially be treated.

“Bacteria infecting the bloodstream can be lethal,” said Arden Baylink, a professor at WSU’s College of Veterinary Medicine and corresponding author for the research. “We learned some of the bacteria that most commonly cause bloodstream infections actually sense a chemical in human blood and swim toward it.”

Baylink and the lead author on the study, WSU Ph.D. student Siena Glenn, found at least three types of bacteria, Salmonella enterica, Escherichia coli and Citrobacter koseri, are attracted to human serum. These bacteria are a leading cause of death for people who have inflammatory bowel diseases (IBD), about 1% of the population. These patients often have intestinal bleeding that can be entry points for the bacteria into the bloodstream.

Using a high-powered microscope system designed by Baylink called the Chemosensory Injection Rig Assay, the researchers simulated intestinal bleeding by injecting microscopic amounts of human serum and watching as the bacteria navigated toward the source. The response is rapid — it takes less than a minute for the disease-causing bacteria to find the serum.

As part of the study, the researchers determined Salmonella has a special protein receptor called Tsr that enables bacteria to sense and swim toward serum. Using a technique called protein crystallography, they were able to view the atoms of the protein interacting with serine. The scientists believe serine is one of the chemicals from blood that the bacteria sense and consume.

“By learning how these bacteria are able to detect sources of blood, in the future we could develop new drugs that block this ability. These medicines could improve the lives and health of people with IBD who are at high risk for bloodstream infections,” Glenn said.

Scientists Zealon Gentry-Lear, Michael Shavlik, and Michael Harms of the University of Oregon, and Tom Asaki, a mathematician at WSU, contributed to the research. The study was funded by WSU and the National Institute of Allergy and Infectious Diseases.